データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
1402-82-0CCC(C)CCCCC/C=C/CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)[C@@H]1NC(=O)[C@H]2CCCCN2C1=O)C(C)C)[C@H](C)N)[C@@H](C)C(=O)OXBNDESPXQUOOBQ-LSMLZNGOSA-N1402-82-0DTXSID101017657CHEMBL2103921安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
使用Amphomycin is a lipopeptide antibiotic produced by Streptomycetes and Actinoplanes, initially reported by researchers at Bristol-Myers in 1953 from Streptomyces canus. Amphomycin was marketed as a complex of closely related analogues in the 1950s and 1960s. Structure elucidation was not completed until 2000. Amphomycin is active against Gram positive bacteria, inhibiting peptidoglycan synthesis and blocking cell wall development. Amphomycin is closely related to a number of “lost” antibiotics, aspartocin, crystallomycin, glumamycin, friulimicin, laspartocin, tsushimycin and zaomycin. Interest in amphomycin was re-awakened with the discovery of friulimicin activity against antibiotic resistant strains.
現在のフィルター条件では反応記録がありません。
読み込み中…